PDS Biotechnology (PDSB) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on PDS0301, a tumor-targeted IL-12 immunocytokine intended to modify the tumor microenvironment and enhance anti-cancer therapies; development prioritizes colorectal cancer and other indications.

• Also develops Versamune® oncology and Infectimune® infectious-disease platforms; seeks strategic partnerships to further develop PDS0101.

Financial performance and metrics

• September 2026 private placement generated gross proceeds of ~$11.3m; proceeds were designated for debt repayment, working capital and general corporate purposes, including clinical development and R&D.

• An April 2026 promissory note had $6m aggregate principal and 10% annual interest; it was redeemed in full for ~$4.6m on September 14, 2026, and terminated.

• 105,005,429 common shares were outstanding as of October 9, 2026; closing share price was $1.60 on October 13, 2026.

• VERSATILE-002 Phase 2 results reported median overall survival of 39.3 months in first-line, immune-checkpoint-inhibitor-naïve patients with HPV16-positive recurrent/metastatic head and neck cancer and PD-L1 CPS ≥1.

Use of proceeds and capital allocation

• Resale proceeds go to selling stockholders; cash warrant exercises would provide proceeds to fund working capital and general corporate purposes.

• September placement proceeds were allocated to repay outstanding indebtedness and support working capital, clinical programs, R&D, capital expenditures, and G&A.

• A workforce reduction affecting ~36% of staff was announced in August 2026 to align expenses with strategic priorities and focus resources on PDS0301; completion was expected in Q3 2026.